REGENERON PHARMACEUTICALS, INC. (REGN)

Earnings Overview

Next Earnings Date

April 29, 2026

REGENERON PHARMACEUTICALS, INC. (REGN) reported Dec-25 earnings with earnings per share of $11.44, a decrease of 5% compared to the same quarter last year. REGN revenue came in at $3.88 billion, up 3% year-over-year. The next REGENERON PHARMACEUTICALS, INC. earnings report is expected on April 29, 2026.

Annual

YearEPSYoYRevenue (Bil)YoY
202544.38-3%14.34+1%
202445.64+4%14.20+8%
202343.78+3%13.12+8%

Quarterly

QuarterEPSYoYRevenue (Bil)YoY
Dec-2511.44-5%3.88+3%
Sep-2511.83-5%3.75+1%
Jun-2512.89+12%3.68+4%
Mar-258.22-14%3.03-4%

Get the full REGN analysis

Sign up for earnings surprises, estimates, performance scores, insider trades, institutional ownership, and more.

No credit card required

Earnings Call Summary

AI-generated sentiment, guidance, catalysts & risks

Earnings Surprises

Beat/miss data for every quarter

Performance Score

Proprietary earnings quality rating

Insider Trading

Recent insider buys and sells

Institutional Ownership

Top holders and quarterly changes

Earnings Calendar

Upcoming earnings dates and estimates

Stock Screener

Filter stocks by earnings metrics

Analyst Estimates

Forward EPS and revenue estimates

Price Targets

Analyst price targets and upgrades/downgrades

REGN Beat/Miss History

REGENERON PHARMACEUTICALS, INC. has beaten analyst EPS estimates in 20 of the last 23 quarters. The largest earnings beat was +52.9% in Jun-25. The largest miss was -8.3% in Mar-22. On the revenue side, REGN exceeded estimates in 19 of 23 quarters.

REGN Growth Trajectory

REGENERON PHARMACEUTICALS, INC. EPS growth has ranged from -62% to +260% over the last 19 quarters. REGN posted positive EPS growth in 10 of 19 quarters. EPS growth has been decelerating over the most recent quarters.

Revenue growth for REGN ranged from -44% to +163% over the same period. The most recent quarter brought in $3.88 billion in revenue.

REGN Annual Performance

In 2025, REGENERON PHARMACEUTICALS, INC. earned $44.38 per share, down 3% from 2024 when EPS was $45.64. Full-year 2025 revenue for REGN was $14.34 billion, an increase of 1% year-over-year.